Companion Spine has entered an agreement to acquire the Coflex interlaminar stabilization and CoFix posterior MIS fusion system implants, Paradigm Spine, its subsidiaries, and all Paradigm Spine-related global business activity from Xtant Medical.

Wurmlingen, Germany-based Paradigm Spine designs, develops, markets, and distributes a range of spine implants to treat spine pain-related disorders. Coflex and CoFix—available in the U.S.—have been on the market for 12 years in the U.S. and 20 years outside the U.S. They are distributed to over 60 countries, with more than 280,000 Coflex devices and over 130,000 CoFix systems implanted globally.

Xtant Medical acquired the Coflex and CoFix products from Surgalign for $17 million in 2023.

Paradigm Spine products available only outside the U.S. include the HPS 2.0 hybrid performance system, DSS dynamic stabilization system, and DCI dynamic cervical implant. Together with its portfolio, Companion Spine will be able to treat the full range of lumbar spinal stenosis and degenerative disc disease conditions across the spectrum of disease progression.

The transaction positions the company as the holder of the world’s largest, most comprehensive MIS posterior dynamic spine stabilization and motion preserving solutions portfolio.

“This is an incredible opportunity to bring together two highly complementary product offerings to enhance Companion Spine’s ability to provide solutions across the full spectrum of pathological stages of LSS and DDD,” said Anthony G. Viscogliosi, executive chairman and CEO of Companion Spine. “We are confident we will create value for our stakeholders, building on our shared history with the most experienced management team in posterior dynamic spine stabilization and motion preservation. Paradigm Spine was previously part of the Viscogliosi Brothers portfolio and sold in 2019. We are now re-acquiring it, bringing it back into our portfolio through Companion Spine. We know the business, its customers and its talented team very well. There is much to look forward to as we build upon this momentum to realize our vision and continue to support patients and surgeons globally.”

Following the close of the acquisition, Companion Spine will become the first sole source provider of a full range of an indication-specific product portfolio for customers using dynamic stabilization and motion preservation implants.

“This is a terrific transaction for both organizations,” said Sean Browne, CEO of Xtant Medical. “For Xtant, the sale of these business units allows us to strategically focus on our core business, while meaningfully reducing our debt and improving our balance sheet. Moreover, these fantastic motion preservation technologies such as Coflex, HPS 2.0 and DCI will get the kind of focus only the Viscogliosi Brothers and Companion Spine can provide to optimize their commercial development. This type of development is in the DNA of the Viscogliosi Brothers, while it is far afield of Xtant Medical’s core competencies; so we expect big things for Companion Spine in the years ahead.”